Скачать или смотреть Cybin Helping the Pandemic Frontline Heroes | Numinus to Uplist to the TSX ( CYBN, NUMI)

On today’s $PSYC Business Roundup, we are looking at some recent developments for Cybin (NYSE: CYBN) and Numinus Wellness (OTC: NUMIF, TSX.V: NUMI).

To start, Cybin has received the green light from FDA to begin a Phase 2 trial to treat frontline clinicians experiencing COVID-related distress. This study, which is co-sponsored with University of Washington aims to treat symptoms of depression, anxiety, burnout and post-traumatic stress (PTSD) among 30 frontline doctors, nurses and healthcare professionals.
The study will be double-blinded and placebo controlled, and will use protocols developed by Cybin’s psychedelic therapy clinician training program, EMBARK.
The primary end point will be 4 weeks after the dose session, and then we will compare the depression, anxiety, burnout and PTSD levels of those in the psilocybin group, as compared to the control group.

This is important for 2 reasons:

First, if the trial is successful, we can scale the treatment to more front-line healthcare workers, perhaps after a phase 3 trial. Unfortunately, the pandemic has taken its mental health toll on our front line medical workers.
For example, one recent study showed that among American health care workers,
38% reported anxiety/depression, 43% suffered work overload, and 49% had burnout during the pandemic. Our healthcare workers have been heroes over the past couple of years, so anything that can ease their burden is important.

Second, as CEO of Cybin, Doug Drysdale says, Cybin can use this trial to gain insights on how to run future trials, specifically with their lead drug candidate CYB-003, a modified version of psilocybin.

Our second important news for the week includes Numinus Wellness (OTC: NUMIF, TSX.V: NUMI). Recently, Numinus announced a novel, proprietary method for psychedelic mushroom compound screening.

This will allow NUMI to measure the amount of therapeutic compounds like psilocybin and psilocin that are present in their mushrooms, as well as screen for any potential contaminants and residues. This is important for Numinus for 2 reasons:

First, Numi, unlike many other companies, uses naturally grown psilocybin mushrooms, as compared to synthetically created psilocybin. While they maintain that this will ultimately be cheaper to produce and better for the patients, it does mean that they need to be able to accurately measure the many different compounds within their mushrooms. Today’s news goes a long way towards this goal, and will also help them in conversations with regulators.

Second, Numinus earns much of its revenue from selling its lab services to third parties.
This will add another service the company can offer to those working with mushrooms.
One last note for Numinus, the company announced that they have been given approval to uplist their stock in Canada from the TSX Venture Capital Exchange, to the TSX proper.
The company's CEO, Payton Nyquevest said that "this is an important milestone for Numinus, as we take key steps to heighten our corporate profile and reach a broader range of investors."

#cybin #cybn #Numinus